Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice |
| |
| Affiliation: | 1. McMaster University, Canada;2. Hospital for Special Surgery, Weill Cornell Medicine, United States;1. Department of Oral and Maxillofacial Surgery, University Hospital “Klinikum rechts der Isar”, München, Germany;2. Department of Radiation Oncology, University Hospital “Klinikum rechts der Isar”, München, Germany |
| |
| Abstract: | Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) represent a family of systemic inflammatory diseases occurring in adults aged 50 years and above. Clinical presentation of PMR/GCA can be variable, making diagnosis at times challenging. There has been an increased appreciation of the role of various large-vessel imaging modalities to help confirm a diagnosis of GCA. Systemic corticosteroids (CS) remain the mainstay of treatment for both PMR and GCA, yet both relapses and CS-related side effects are common. Recent research has demonstrated efficacy of certain biologic agents in these diseases, with particular emphasis on the role of interleukin-6 (IL-6) blockade in GCA. This chapter discusses the latest updates on the diagnosis and treatment of PMR/GCA, with an emphasis on clinical care. |
| |
| Keywords: | Polymyalgia rheumatica Giant cell arteritis Corticosteroids Biologics Large-vessel vasculitis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
